Aytu BioPharma (AYTU) Competitors $2.34 -0.05 (-1.89%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. ARTV, ABVC, BYSI, QNTM, VNRX, GANX, INKT, JATT, NRXP, and DTILShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Artiva Biotherapeutics (ARTV), ABVC BioPharma (ABVC), BeyondSpring (BYSI), Quantum Biopharma (QNTM), VolitionRx (VNRX), Gain Therapeutics (GANX), MiNK Therapeutics (INKT), JATT Acquisition (JATT), NRx Pharmaceuticals (NRXP), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors Artiva Biotherapeutics ABVC BioPharma BeyondSpring Quantum Biopharma VolitionRx Gain Therapeutics MiNK Therapeutics JATT Acquisition NRx Pharmaceuticals Precision BioSciences Aytu BioPharma (NASDAQ:AYTU) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability. Do insiders and institutionals have more ownership in AYTU or ARTV? 33.5% of Aytu BioPharma shares are owned by institutional investors. 3.6% of Aytu BioPharma shares are owned by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer AYTU or ARTV? Aytu BioPharma currently has a consensus target price of $9.17, suggesting a potential upside of 292.58%. Artiva Biotherapeutics has a consensus target price of $17.00, suggesting a potential upside of 468.56%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is AYTU or ARTV more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -20.43%. Aytu BioPharma's return on equity of 13.77% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aytu BioPharma-20.43% 13.77% 3.28% Artiva Biotherapeutics N/A -42.60%-37.76% Which has better valuation & earnings, AYTU or ARTV? Aytu BioPharma has higher revenue and earnings than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAytu BioPharma$66.38M0.35-$13.56M-$2.82-0.83Artiva Biotherapeutics$250K292.18-$65.37MN/AN/A Does the media favor AYTU or ARTV? In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 2 mentions for Aytu BioPharma. Artiva Biotherapeutics' average media sentiment score of 0.62 beat Aytu BioPharma's score of 0.23 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aytu BioPharma Neutral Artiva Biotherapeutics Positive Which has more risk and volatility, AYTU or ARTV? Aytu BioPharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500. SummaryArtiva Biotherapeutics beats Aytu BioPharma on 9 of the 14 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.14M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-0.8323.0384.9327.30Price / Sales0.35268.08515.79197.96Price / Cash6.2346.9537.5761.53Price / Book1.1110.5412.426.82Net Income-$13.56M-$52.58M$3.32B$276.59M7 Day Performance-1.48%0.59%0.53%0.00%1 Month Performance0.21%15.50%10.24%7.96%1 Year Performance1.97%18.01%75.92%35.10% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma3.6393 of 5 stars$2.34-1.9%$9.17+292.6%+5.3%$23.14M$66.38M-0.83160Analyst ForecastARTVArtiva Biotherapeutics3.3307 of 5 stars$2.93-0.7%$17.00+480.2%-79.9%$72.06MN/A0.0081ABVCABVC BioPharma0.8605 of 5 stars$3.13+4.3%N/A+495.9%$70.63M$391.24K-18.4130Gap UpBYSIBeyondSpringN/A$1.78+1.7%N/A-34.1%$70.58MN/A0.0080News CoverageGap DownQNTMQuantum Biopharma0.4253 of 5 stars$17.88-3.1%N/A+231.7%$70.40MN/A-1.28N/AVNRXVolitionRx2.3145 of 5 stars$0.64-0.5%$3.50+442.8%-35.6%$69.38M$1.32M-1.7980GANXGain Therapeutics2.9489 of 5 stars$2.22+15.6%$8.00+260.4%-13.2%$69.02M$50K-3.5220Analyst ForecastGap DownHigh Trading VolumeINKTMiNK Therapeutics2.8988 of 5 stars$15.19+1.1%$37.50+146.9%+108.1%$67.91MN/A-5.2730JATTJATT AcquisitionN/A$3.93-4.1%N/A-52.7%$67.79MN/A0.003Gap DownHigh Trading VolumeNRXPNRx Pharmaceuticals3.3154 of 5 stars$3.35+2.4%$34.50+929.9%+131.1%$64.78MN/A-1.502DTILPrecision BioSciences3.8318 of 5 stars$5.67+4.2%$47.00+728.9%-34.3%$64.12M$68.70M-0.64200 Related Companies and Tools Related Companies Artiva Biotherapeutics Alternatives ABVC BioPharma Alternatives BeyondSpring Alternatives Quantum Biopharma Alternatives VolitionRx Alternatives Gain Therapeutics Alternatives MiNK Therapeutics Alternatives JATT Acquisition Alternatives NRx Pharmaceuticals Alternatives Precision BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
